Reading ICCC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ICCC free→Reading ICCC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ICCC free→QuarterlyIQ Insights · ICCC
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Regulation FD Disclosure In late December 2025 and early January 2026, ImmuCell Corporation (“ImmuCell” or the “Company”) announced the suspension of plans to manufacture its Re-Tain® product in-house, and instead convert most of the related facilities and equipment for expanded production of the Company’s flagship First Defense® product line. On June 4, 2026, ImmuCell’s Board of Directors authorized a manufacturing capacity expansion program to execute on that strategy. The first phase, whic…
Results of Operations and Financial Condition On May 14, 2026 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject…
Entry into a Material Definitive Agreement On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies. As previously reported, that agreement expired March 31, 2026. Under the Settlement Deed, Norbrook has agreed to pay ImmuCell the s…
Departure of Directors; Election of Directors. (b) As previously disclosed in the Company’s Current Report on Form 8-K filed on February 9, 2026, Bryan K. Gathagan gave the Company notice that he preferred not to run for re-election to the Company’s Board of Directors (the “Board”) at the 2026 Annual Meeting of Stockholders. At a meeting of the Board held on April 7, 2026, Mr. Gathagan tendered his retirement from the Board effective April 15, 2026. During the same April 7, 2026 meeting of th…
Results of Operations and Financial Condition. On April 8, 2026 ImmuCell Corporation (the "Company") issued a press release announcing a 28.4% increase in product sales in Q1 of 2026 as compared to Q1 of 2025, based on preliminary, unaudited sales results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposed of S…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) As previously disclosed in the Company’s Current Report on Form 8-K filed on February 9, 2026, Steven A. Rosgen gave the Company notice that he preferred not to run for re-election to the Company’s Board of Directors (the “Board”) at the 2026 Annual Meeting of Shareholders. On March 12, 2026, Mr. Rosgen tendered his resignation from the Board,…
shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated March 4, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document ) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 4, 2026 IMMUCELL CORPORATION By: /s/ Timothy C. Fiori Timothy C. Fiori Chief Financial Officer Exh…
Departure of Directors or Certain Officers, Election of Directors. Two Company directors (Steven A. Rosgen and Bryan K. Gathagan) have separately given notice that they prefer not to run for re-election at the 2026 Annual Meeting of Shareholders. Both have been supportive of the Company’s new strategic direction and management team, but each cited time constraints from full-time leadership roles at their respective companies. The Nominating Committee has recently been evaluating possible chan…
Entry into a Material Definitive Agreement The information set forth in
Departure of Directors or Certain Officers, Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective as of January 27, 2026, the Company entered into new employment agreements with Timothy C. Fiori, the Company’s Chief Financial Officer, and Bobbi Jo Brockmann, the Company’s Senior Vice President of Sales and Marketing. Pursuant to the new employment agreements, Mr. Fiori will be compensated at an annual base salary of $315,000 and Ms. B…
Results of Operations and Financial Condition On January 8, 2026, ImmuCell Corporation (the “Company”) issued a press release announcing its preliminary, unaudited sales results for the three-month and twelve-month periods ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto, and is incorporated herein by reference. The information in this report and the exhibit attached hereto are being furnished and shall not be deemed filed for purposes of the Securities…
Material Impairments. In its January 8, 2026 press release (see Exhibit 99.1, incorporated herein by reference), the Company announced that it will record approximately $3.6 million in non-cash impairment write-downs during the three-month period ended December 31, 2025. 1. As announced on December 24, 2025, the Company decided to pause further investment in Re-Tain® after receiving an FDA Incomplete Letter because the Company’s contract manufacturer had not satisfactorily addressed previousl…
ImmuCell Corporation (“ImmuCell”) has announced strategy changes (see
Results of Operations and Financial Condition On November 13, 2025 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in the Company’s Current Report on Form 8-K filed on September 30, 2025, the Company elected Olivier te Boekhorst to serve as its President and Chief Executive Officer starting on November 1, 2025. As of that date, Michael F. Brigham stepped down as President, CEO, Secretary, and Treasurer and assumed the position of Special…
shall be deemed to be furnished, and not filed: 99.1 Press Release of the Company dated November 4, 2025. 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: November 4, 2025 By: /s/ Timothy C. Fiori Timothy C. Fiori Chief Financial Officer 2 Exh…
shall be deemed to be furnished, and not filed: 99.1 Press Release of the Company dated October 7, 2025. 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: October 7, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Executive…
shall be deemed to be furnished, and not filed: 10.1 Employment Agreement between the Company and Olivier te Boekhorst dated as of September 29, 2025. 10.2 Confidential Information, Inventions and Noncompete Agreement between the Company and Olivier te Boekhorst, signed September 29, 2025 and effective upon commencement of employment. 99.1 Press Release of the Company dated September 29, 2025. 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant…
Entry into a Material Definitive Agreement The information set forth in
Departure of Directors or Certain Officers, Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The Board of Directors of ImmuCell Corporation (the Company) has elected Olivier te Boekhorst, age 54, to serve as its President and Chief Executive Officer starting November 1, 2025. Mr. te Boekhorst is currently an Operating Partner of Archimed, a global investment firm based in New York City and Lyon, France. He has served since August 2024 as C…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information included in
Entry into a Material Definitive Agreement On August 20, 2025, ImmuCell Corporation (the “Company”) entered into an Allonge to and Amendment of Line of Credit (the “Allonge”) between the Company and Maine Community Bank (MCB) pursuant to which the Company’s $1 million line of credit with MCB was extended through September 11, 2026. Interest on borrowings against the Line of Credit is variable at the National Prime Rate per annum.
shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated August 14, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: August 14, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief E…
Entry into a Material Definitive Agreement
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant On August 7, 2025, ImmuCell Corporation (the “Company”) entered into a Loan Agreement, Promissory Note, and other definitive agreements covering a loan transaction with Maine Community Bank (MCB). Proceeds from such loan transaction in the principal amount of $2,327,119, and bearing interest at a fixed rate of 6.5% per annum, were used to pay off a loan from MCB with an outstandin…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.